Table 2 Eosinophil surface proteins reported to respond to intervention
Protein | Observation | Reference |
|---|---|---|
αL integrin (CD11a) | Decreased by anti-IL-5 (mepolizumab) after segmental lung antigen challenge (in mild allergic asthma) | [1] |
αM integrin (CD11b) | Decreased by anti-IL-5 (mepolizumab) after segmental lung antigen challenge (in mild allergic asthma) | [1] |
β2 integrin (CD18) | Decreased by anti-IL-5 (mepolizumab) after segmental lung antigen challenge (in mild allergic asthma) | [1] |
Decreased by topical corticosteroids (in EoE) | [6] | |
CCR3 (CD193) | Decreased by anti-IL-5 (mepolizumab) (in EoE) | [11] |
IL-2Rα (CD25) | Decreased by corticosteroid and other anti-inflammatory drug treatment | [7] |
IL-5Rα (CD125) | Increased by anti-IL-5 (mepolizumab) | [1] |
PSGL-1 (CD162) | Decreased by anti-IL-5 (mepolizumab) after segmental lung antigen challenge (in mild allergic asthma) | [1] |
Activated β2 integrin (CD18) | Intermediate state (recognized by mAb KIM-127) decreased by anti-IL-5 (mepolizumab) (in mild allergic asthma) | [1] |